IR@PKUHSC  > 北京大学第一临床医学院  > 神经内科
学科主题临床医学
Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study
Huang, Yining1; Cheng, Yan2; Wu, Jiang3; Li, Yansheng4; Xu, En5; Hong, Zhen6; Li, Zhengyi7; Zhang, Weiwei8; Ding, Meiping9; Gao, Xuguang10; Fan, Dongsheng11; Zeng, Jinsheng12; Wong, Kasing13; Lu, Chuanzhen6; Xiao, Jiangxi1; Yao, Chen1; CASISP Cooperation Investigators
刊名LANCET NEUROLOGY
2008-06-01
DOI10.1016/S1474-4422(08)70094-2
7期:6页:494-499
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Clinical Neurology
研究领域[WOS]Neurosciences & Neurology
关键词[WOS]PLACEBO-CONTROLLED TRIAL ; HIGH-RISK PATIENTS ; CLOPIDOGREL ; EVENTS ; PROLIFERATION ; INHIBITOR ; SUBTYPES ; ATTACK ; CHINA ; MICE
英文摘要

Background Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community. Cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, is an alternative to aspirin that works through a different mechanism. This trial aimed to compare the efficacy and safety of cilostazol with that of aspirin for the long-term prevention of the recurrence of ischaemic stroke.

Methods 720 patients (mean age 60.2 years, SD 9.86) who had had an ischaemic stroke within the previous 1-6 months were enrolled consecutively in a prospective, multicentre, double-blind, randomised trial. 360 patients were randomly assigned to receive cilostazol and 360 patients to receive aspirin. Analysis was by intention to treat. Patients in both groups took the medication for 12-18 months. The primary endpoint was any recurrence of stroke (ischaemic stroke, haemorrhagic stroke, or subarachnoid haemorrhage) during the trial period. All patients had MRI with T1 MRI, T2 MRI, diffusion-weighted imaging (DWI), T2 fluid-attenuated inversion recovery (FLAIR), and T2 gradient echo imaging (T2*) at the beginning and the end of the study. This trial is registered with ClinicalTrials.gov, number NCT00202020.

Findings The average duration of treatment was 740 person-years, and 719 patients were analysed (360 in the cilostazol group and 359 in the aspirin group). The primary endpoint was reported in 12 patients in the cilostazol group and in 20 patients in the aspirin group. The estimated hazard ratio, calculated with Kaplan-Meier curves (risk of primary endpoint in cilostazol group vs aspirin group), was 0.62 (95% CI 0.30-1.26; p=0.185). Symptomatic cerebral haemorrhage was reported in six patients: one in the cilostazol group and five in the aspirin group. Asymptomatic cerebral haematoma was found in four patients in the aspirin group and one patient in the cilostazol group. Brain bleeding events were significantly more common in the aspirin group than in the cilostazol group (7 vs 1, p=0.034). All of the six patients with symptomatic haemorrhage had previous cerebral microbleeds in the area where the haematoma was located.

Interpretation The results of this pilot study showed no significant difference in the rate of recurrence of stroke between patients with ischaemic stroke who were randomly assigned to take either cilostazol or aspirin. The lower rates of ischaemic and haemorrhagic stroke in the cilostazol group suggest that cilostazol might be a more effective and safer alternative to aspirin for Chinese patients with ischaemic stroke; however, a larger phase III trial is required to confirm this.

语种英语
WOS记录号WOS:000256207800011
引用统计
被引频次:142[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/55587
专题北京大学第一临床医学院_神经内科
作者单位1.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
2.Peking Univ, Hosp 3, Beijing 100871, Peoples R China
3.Tianjin Med Univ, Affiliated Hosp, Tianjin, Peoples R China
4.Jilin Univ, Hosp 1, Changchun 130023, Peoples R China
5.Zhejiang Univ, Hosp 2, Hangzhou, Zhejiang, Peoples R China
6.Fudan Univ, Huashan Hosp, Shanghai 200433, Peoples R China
7.Xian Jiaotong Univ, Hosp 1, Xian 710049, Peoples R China
8.Gen Hosp, Beijing Mil Branch, Beijing, Peoples R China
9.Peking Univ, Hosp 1, Dept Neurol, Beijing 100034, Peoples R China
10.Shanghai Jiao Tong Univ, Sch Med, Affiliated Renji Hosp, Shanghai 200030, Peoples R China
11.Guangzhou Med Coll, Affiliated Hosp 2, Guangzhou, Peoples R China
12.Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China
13.Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
推荐引用方式
GB/T 7714
Huang, Yining,Cheng, Yan,Wu, Jiang,et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study[J]. LANCET NEUROLOGY,2008,7(6):494-499.
APA Huang, Yining.,Cheng, Yan.,Wu, Jiang.,Li, Yansheng.,Xu, En.,...&CASISP Cooperation Investigators.(2008).Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.LANCET NEUROLOGY,7(6),494-499.
MLA Huang, Yining,et al."Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study".LANCET NEUROLOGY 7.6(2008):494-499.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Huang, Yining]的文章
[Cheng, Yan]的文章
[Wu, Jiang]的文章
百度学术
百度学术中相似的文章
[Huang, Yining]的文章
[Cheng, Yan]的文章
[Wu, Jiang]的文章
必应学术
必应学术中相似的文章
[Huang, Yining]的文章
[Cheng, Yan]的文章
[Wu, Jiang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。